JP2010525042A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525042A5
JP2010525042A5 JP2010504828A JP2010504828A JP2010525042A5 JP 2010525042 A5 JP2010525042 A5 JP 2010525042A5 JP 2010504828 A JP2010504828 A JP 2010504828A JP 2010504828 A JP2010504828 A JP 2010504828A JP 2010525042 A5 JP2010525042 A5 JP 2010525042A5
Authority
JP
Japan
Prior art keywords
sapacitabine
days
treatment cycle
administered
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525042A (ja
JP5852309B2 (ja
Filing date
Publication date
Priority claimed from GB0708021A external-priority patent/GB0708021D0/en
Priority claimed from GB0723723A external-priority patent/GB0723723D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/001424 external-priority patent/WO2008132443A1/en
Publication of JP2010525042A publication Critical patent/JP2010525042A/ja
Publication of JP2010525042A5 publication Critical patent/JP2010525042A5/ja
Application granted granted Critical
Publication of JP5852309B2 publication Critical patent/JP5852309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504828A 2007-04-25 2008-04-24 増殖性疾患を治療するためのサパシタビンの使用 Expired - Fee Related JP5852309B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0708021.1 2007-04-25
GB0708021A GB0708021D0 (en) 2007-04-25 2007-04-25 Use
GB0723723A GB0723723D0 (en) 2007-12-04 2007-12-04 Use
GB0723723.3 2007-12-04
PCT/GB2008/001424 WO2008132443A1 (en) 2007-04-25 2008-04-24 Use of sapacitabine to treat proliferative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014170018A Division JP5892565B2 (ja) 2007-04-25 2014-08-25 増殖性疾患を治療するためのサパシタビンの使用

Publications (3)

Publication Number Publication Date
JP2010525042A JP2010525042A (ja) 2010-07-22
JP2010525042A5 true JP2010525042A5 (enExample) 2011-06-02
JP5852309B2 JP5852309B2 (ja) 2016-02-03

Family

ID=39719125

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504828A Expired - Fee Related JP5852309B2 (ja) 2007-04-25 2008-04-24 増殖性疾患を治療するためのサパシタビンの使用
JP2014170018A Expired - Fee Related JP5892565B2 (ja) 2007-04-25 2014-08-25 増殖性疾患を治療するためのサパシタビンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014170018A Expired - Fee Related JP5892565B2 (ja) 2007-04-25 2014-08-25 増殖性疾患を治療するためのサパシタビンの使用

Country Status (6)

Country Link
US (2) US8536188B2 (enExample)
EP (1) EP2148676B1 (enExample)
JP (2) JP5852309B2 (enExample)
ES (1) ES2587381T3 (enExample)
PL (1) PL2148676T3 (enExample)
WO (1) WO2008132443A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008132443A1 (en) 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
AU2009248037A1 (en) * 2008-05-15 2009-11-19 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer combination therapy
HUE046177T2 (hu) * 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
WO2013171473A1 (en) * 2012-05-15 2013-11-21 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
AU2014203896B2 (en) * 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341260C2 (ru) * 2002-03-08 2008-12-20 Новартис Аг Комбинации, включающие производные эпотилона и алкилирующие агенты
US20050014716A1 (en) * 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
EP1849470B2 (en) * 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
US20090227674A1 (en) * 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008132443A1 (en) 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease

Similar Documents

Publication Publication Date Title
JP2025020147A5 (enExample)
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
JP2012509889A5 (enExample)
JP2009539769A5 (enExample)
RU2013102398A (ru) Лечение рака крови
JP2012521435A5 (enExample)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2019526595A5 (enExample)
JP2011529968A5 (enExample)
JP2020528455A5 (enExample)
JP2006513184A5 (enExample)
JP2017537927A5 (enExample)
JP2018522028A5 (enExample)
JP2024016209A5 (enExample)
JP2013541587A5 (enExample)
Bokemeyer et al. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer
JP2021530502A5 (enExample)
RU2346686C2 (ru) Комбинации, включающие эпотилоны и антиметаболиты
JP2013540734A5 (enExample)
JP2018506533A5 (enExample)
JP2006503095A5 (enExample)
JP2007534634A5 (enExample)
RU2006132069A (ru) Противораковые терапии
Zatloukal et al. Gemcitabine/carboplatin in advanced non-small cell lung cancer
JP2023501317A5 (enExample)